Showing results (1801-1810 of 1,865) with videos related to

Sort By:
Pageof 187
Cancer Cell|August 30, 2016
GOLM1 Modulates EGFR/RTK Cell-Surface Recycling to Drive Hepatocellular Carcinoma MetastasisQing-Hai Ye, Wen-Wei Zhu, Ju-Bo Zhang, et al.
American Journal of Hematology|December 25, 2015
Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remissionMatthew D Seftel, Donna Neuberg, Mei-Jie Zhang, et al.
Journal of the National Cancer Institute|April 19, 2024
Radiomic signatures associated with tumor immune heterogeneity predict survival in locally recurrent nasopharyngeal carcinomaDa-Feng Lin, Hai-Lin Li, Ting Liu, et al.
Molecular Cell|February 16, 2016
Nuclear m(6)A Reader YTHDC1 Regulates mRNA SplicingWen Xiao, Samir Adhikari, Ujwal Dahal, et al.
European Journal of Pain (London, England)|April 18, 2020
A multi-center international study of acupuncture for lateral elbow pain - Results of a randomized controlled trialMarcus Gadau, Shi Ping Zhang, Fu Chun Wang, et al.
Signal Transduction and Targeted Therapy|July 16, 2021
Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trialsFan-Yue Meng, Fan Gao, Si-Yue Jia, et al.
American Journal of Hematology|October 7, 2016
Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemiaAshley Rosko, Hai-Lin Wang, Marcos de Lima, et al.
Molecular Plant|March 31, 2020
A Strigolactone Biosynthesis Gene Contributed to the Green Revolution in RiceYuexing Wang, Lianguang Shang, Hong Yu, et al.
Cell Stem Cell|February 17, 2015
m(6)A RNA methylation is regulated by microRNAs and promotes reprogramming to pluripotencyTong Chen, Ya-Juan Hao, Ying Zhang, et al.
American Journal of Hematology|March 20, 2024
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapyMatthew A Lunning, Hai-Lin Wang, Zhen-Huan Hu, et al.
Pageof 187